Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Herpes Simplex Virus Vaccines
Researchers from Harvard University detail new studies and findings in the area of herpes simplex virus vaccines
April 29th, 2009
A new study, 'High-level expression of glycoprotein D by a dominant-negative HSV-1 virus augments its efficacy as a vaccine against HSV-1 infection,' is now available. "Using the T-REx (Invitrogen, Carlsbad, CA) gene switch technology, we previously generated a dominant-negative herpes simplex virus (HSV)-1 recombinant, CJ83193, capable of inhibiting its own replication as well as that of wild-type HSV-1 and HSV-2. It has been further demonstrated that CJ83193 is an effective vaccine against HSV-1 infection in a mouse ocular model," scientists writing in the Journal of Investigative Dermatology report. "To ensure its safety and augment its efficacy, we generated...
Source: Vaccine Weekly (2009-04-29)
|
